EVGN
Evogene Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.54
−1.30%Aug 31, 2026, 12:00 UTC
Evogene Ltd. responded to dissident shareholders, urging shareholders to vote for its nominees at the upcoming Annual General Meeting on September 4, 2026.
Source:Aug 18, 2026, 12:04 UTC
Evogene Ltd. reported its financial results for the second quarter and first half of 2026, with a net loss of approximately $1.8 million in Q2 2026, compared to $4.7 million in Q2 2025.
Jul 22, 2026, 12:00 UTC
Evogene Ltd. and ELEO Inc. announced a strategic scientific collaboration to discover and develop next-generation oral small-molecule PCSK9 pathway inhibitors for hyperlipidemia and cardiovascular diseases.
Source:Jul 15, 2026, 11:30 UTC
AgPlenus Ltd. launched a novel AI model for predicting antifungal potency, expanding its ChemPass AI for Ag capabilities.
Jul 8, 2026, 11:00 UTC
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery announced a strategic joint initiative to accelerate AI-driven small-molecule drug discovery, supporting Israel's academic innovation ecosystem.
Source:Jun 2, 2026, 11:00 UTC
Evogene announced the successful completion of the Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab.
Source: